Coldstream Capital Management Inc. Purchases 995 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Coldstream Capital Management Inc. raised its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 11.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,705 shares of the medical research company's stock after purchasing an additional 995 shares during the period. Coldstream Capital Management Inc.'s holdings in Thermo Fisher Scientific were worth $5,972,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Geode Capital Management LLC increased its stake in Thermo Fisher Scientific by 1.7% during the third quarter. Geode Capital Management LLC now owns 7,659,943 shares of the medical research company's stock valued at $4,719,477,000 after purchasing an additional 127,564 shares during the last quarter. Greenwood Gearhart Inc. grew its position in shares of Thermo Fisher Scientific by 9.8% during the third quarter. Greenwood Gearhart Inc. now owns 20,579 shares of the medical research company's stock worth $12,730,000 after acquiring an additional 1,837 shares during the last quarter. Prestige Wealth Management Group LLC lifted its position in Thermo Fisher Scientific by 123.0% in the 3rd quarter. Prestige Wealth Management Group LLC now owns 136 shares of the medical research company's stock valued at $84,000 after purchasing an additional 75 shares during the last quarter. Brophy Wealth Management LLC acquired a new position in Thermo Fisher Scientific during the 3rd quarter valued at about $1,568,000. Finally, Vestcor Inc increased its stake in shares of Thermo Fisher Scientific by 10.1% in the third quarter. Vestcor Inc now owns 11,031 shares of the medical research company's stock valued at $6,823,000 after purchasing an additional 1,012 shares during the period. Institutional investors own 89.23% of the company's stock.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $554.29, for a total value of $5,542,900.00. Following the completion of the sale, the chief executive officer now directly owns 121,192 shares in the company, valued at $67,175,513.68. The trade was a 7.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the completion of the sale, the senior vice president now owns 12,736 shares of the company's stock, valued at $7,134,197.76. This trade represents a 13.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 47,150 shares of company stock valued at $25,954,465 over the last three months. 0.34% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on TMO shares. JPMorgan Chase & Co. boosted their price objective on Thermo Fisher Scientific from $650.00 to $670.00 and gave the stock an "overweight" rating in a research report on Friday, September 20th. Redburn Atlantic began coverage on Thermo Fisher Scientific in a research note on Monday, October 14th. They issued a "buy" rating and a $680.00 price target for the company. Stifel Nicolaus cut their price objective on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a "buy" rating on the stock in a research note on Thursday, October 24th. UBS Group raised shares of Thermo Fisher Scientific to a "strong-buy" rating in a research note on Monday, September 16th. Finally, Morgan Stanley upped their price target on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the stock an "overweight" rating in a research note on Friday, September 20th. Four investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Thermo Fisher Scientific currently has an average rating of "Moderate Buy" and a consensus price target of $649.33.

Thermo Fisher Scientific Trading Down 0.3 %

Shares of TMO traded down $1.38 during midday trading on Tuesday, hitting $535.85. The stock had a trading volume of 1,918,736 shares, compared to its average volume of 1,536,297. Thermo Fisher Scientific Inc. has a fifty-two week low of $491.33 and a fifty-two week high of $627.88. The business has a 50-day simple moving average of $556.46 and a two-hundred day simple moving average of $575.08. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. The firm has a market cap of $204.96 billion, a P/E ratio of 33.60, a price-to-earnings-growth ratio of 3.56 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, beating analysts' consensus estimates of $5.25 by $0.03. The company had revenue of $10.60 billion for the quarter, compared to the consensus estimate of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The firm's quarterly revenue was up .2% on a year-over-year basis. During the same quarter in the prior year, the company earned $5.69 EPS. As a group, equities analysts forecast that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current year.

Thermo Fisher Scientific declared that its board has approved a share buyback plan on Friday, November 15th that permits the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization permits the medical research company to reacquire up to 2% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company's leadership believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th will be given a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.29%. The ex-dividend date of this dividend is Friday, December 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.78%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.